Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
OBJECTIVES:
Assess whether 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) at 0.6 mg/kg
per day prevents liver failure in at least 1 patient with tyrosinemia type I.